Option chain shows key data for Humble & Fume Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Humble & Fume Inc.

Humble & Fume Inc (OTC:HUMBF) Stock, Option Chain

stock_whisper_index_logo_6_copy

Analyst Color

Exclusives

Analyst Ratings

Trading Ideas

$BTC

DATS

HUMBF

MARA

PLUG

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

cannabis shacking hands (lindsayfox and Tusumi by Pixabay)(7)

Cannabis

News

Movers & Shakers

AFCG

CSE:HMBL

CSE:IAN

CSE:MMEN

CSE:MRMD

CWBHF

CWEB

FLGC

HMBL

ITHUF

KAVL

MMNFF

MRMD

PCLOF

TSXV:PCLO

UNRIVALED BRANDS INC by Unrivaled Brands, Inc.

UNRV

Top Cannabis Industry Leaders Who Took The Reins In 2023

Earnings

Markets

Cannabis accessory distributor Humble &amp; Fume Inc. (CSE: HMBL) (OTC Pink: HUMBF) reported its full-year financial results for the period ended June 30, 2023.

Canada&#39;s Top Weed Accessory Distributor Will Ramp Up In California, Reports 2023 Sales Uptick

Humble & Fume Inc

CWEN

NDAQ

CNBC Halftime Report Final Trades: Freeport-McMoRan, Clearway Energy, Nasdaq

Ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.42, along with a high estimate of $190.00 and a low estimate of $152.00. Experiencing a 2.74% decline, the current average is now lower than the previous average price target of $171.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655263_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Johnson &amp; Johnson's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$162.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Johnson &amp; Johnson's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Johnson &amp; Johnson's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Breaking Down Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Johnson &amp; Johnson showcased positive performance, achieving a revenue growth rate of 5.25% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Johnson &amp; Johnson's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.51, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Johnson & Johnson Stands With Analysts

Across the recent three months, 5 analysts have shared their insights on OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.0, with a high estimate of $55.00 and a low estimate of $45.00. Surpassing the previous average price target of $48.80, the current average has increased by 2.46%.
<img src="https://www.benzinga.com/files/images/story/2025/1737655248_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of OFG Bancorp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OFG Bancorp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OFG Bancorp compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of OFG Bancorp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OFG Bancorp's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OFG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OFG Bancorp analyst ratings.</a>
<h2>Delving into OFG Bancorp's Background</h2>
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. It provides services in the region of Puerto Rico.
<h3>OFG Bancorp: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, OFG Bancorp showcased positive performance, achieving a revenue growth rate of 2.24% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 28.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): OFG Bancorp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.41%, the company showcases effective utilization of assets.
Debt Management: OFG Bancorp's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About OFG Bancorp

The Leuthold Group just gave investors something new to talk about with the launch of<a href="https://www.benzinga.com/etfs"> its latest ETF</a>, the Leuthold Select Industries ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LST#NYSE">LST</a>). This ETF is the result of an evolution of the Leuthold Select Industries Fund, a mutual fund of more than 20 years that covers everything from small-cap up-and-comers to well-established bigwigs.
Instead of sticking to broad sectors, the fund zeroes in on specific industry groups — about 120. The idea? Find those pockets of the market where companies are poised to outperform.
See Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/01/43160029/tesla-nvidia-etfs-in-the-works-to-tap-rising-interest-in-same-day-stock-options">Tesla, Nvidia ETFs In The Works To Tap Rising Interest In Same-Day Stock Options</a>
"With LST, equity investors who want exposure to a longstanding, proven investment discipline — coupled with the lower cost, operational ease and tax benefits of an ETF — will have that opportunity," said Leuthold CIO Doug Ramsey. "We've been pleased with the performance and market reception of LCR, so it was a natural progression to convert Select Industries to an ETF."
This isn't the Leuthold Group's first time in the ETF space. Their Leuthold Core ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCR#NYSE">LCR</a>) has become popular, blending equity and fixed-income assets. The ETF has more than $80 million in assets under management and a five-star Morningstar rating from the Leuthold Select Industries Fund.
The Leuthold Select Industries ETF comes with a net expense ratio of 0.65%, thanks to a fee waiver. That's a reasonable deal for a fund offering this level of specialization. With markets expected to broaden their growth across sectors in 2025, the ETF is expected to benefit from focusing on advantageous industries. 
The ETF is ideal for investors looking to grow their money over the long term. It is actively managed and has exposure to a broad mix of U.S.-traded equities. 
See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43159032/defiance-quantum-etf-hits-1-billion-milestone-as-ceo-talks-future-of-industry">Defiance Quantum ETF Hits $1 Billion Milestone As CEO Talks Future Of Industry</a></li>
</ul>
Photo: Shutterstock

Long Ideas

New ETFs

ETFs

Managed Portfolio Series Leuthold Select Industries ETF

Leuthold Group Introduces Select Industries ETF, Focus On Companies Ready To Outperform

19 analysts have shared their evaluations of SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.78, along with a high estimate of $21.00 and a low estimate of $3.90. A decline of 25.74% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655240_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of SolarEdge Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$3.90</td>
<td>$3.90</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$12.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SolarEdge Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of SolarEdge Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of SolarEdge Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of SolarEdge Technologies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEDG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SolarEdge Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About SolarEdge Technologies</h2>
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
<h3>Financial Milestones: SolarEdge Technologies's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: SolarEdge Technologies's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -64.03%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: SolarEdge Technologies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -461.98%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SolarEdge Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -78.71%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SolarEdge Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -35.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.79, SolarEdge Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEDG

19 Analysts Assess SolarEdge Technologies: What You Need To Know

In the latest quarter, 3 analysts provided ratings for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $248.67, with a high estimate of $280.00 and a low estimate of $206.00. This upward trend is apparent, with the current average reflecting a 3.61% increase from the previous average price target of $240.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737655229_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Align Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Michael Ryskin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$206.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Tech compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Align Tech's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Align Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Align Tech analyst ratings.</a>
<h2>All You Need to Know About Align Tech</h2>
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
<h3>Financial Milestones: Align Tech's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Align Tech's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.84%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Align Tech's net margin is impressive, surpassing industry averages. With a net margin of 11.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.01%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.85%, the company showcases effective utilization of assets.
Debt Management: Align Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGN

The Analyst Verdict: Align Tech In The Eyes Of 3 Experts

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waste Management, revealing an average target of $232.0, a high estimate of $252.00, and a low estimate of $219.00. This current average reflects an increase of 3.22% from the previous average price target of $224.77. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655222_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Waste Management. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$238.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Coleman</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Jeffrey Goldstein</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$227.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$228.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$220.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Stephanie Yee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$226.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$220.00</td>
<td>$213.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waste Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waste Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waste Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waste Management's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waste Management analyst ratings.</a>
<h2>About Waste Management</h2>
WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
<h3>Waste Management: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Waste Management displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Waste Management's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.55%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.85%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Waste Management's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Waste Management: 13 Analysts Share Their Views

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.63, a high estimate of $95.00, and a low estimate of $60.00. This current average has decreased by 5.94% from the previous average price target of $78.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1737655212_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Exact Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Nowark</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exact Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>Get to Know Exact Sciences Better</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.78%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exact Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exact Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXAS

Forecasting The Future: 19 Analyst Projections For Exact Sciences

Looking into the current session, International Seaways Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) shares are trading at $36.49, after a 0.43% increase. Moreover, over the past month, the stock went up by 1.32%, but in the past year, fell by 31.56%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1737655209_0.png" alt="Past Year Chart" />

<h3>A Look at International Seaways P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 26.02 in the Oil, Gas &amp; Consumable Fuels industry, International Seaways Inc. has a lower P/E ratio of 3.52. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737655209_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

INSW

Price Over Earnings Overview: International Seaways

<a href="https://www.benzinga.com/topic/gold">Gold prices surged</a> to near three-month highs this week, with spot gold reaching $2,755.2 per ounce on Jan. 22, just below its record peak of $2,790.15 from Oct. 31, 2024.
What Happened: As President Donald Trump's tariff announcements reverberate through global markets, gold, often seen as a safe haven during uncertain times, has reclaimed the spotlight. Two of the <a href="https://www.benzinga.com/etfs">most prominent ETFs</a>, SPDR Gold Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) and iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) offer exposure to gold with different features to suit various investor profiles.
Both ETFs use the same benchmark: the LBMA (London Bullion Market Association) Gold Market Fixing Price PM Index.
The SPDR Gold Shares ETF is priced at around $244 per share with a 0.40% expense ratio. The ETF appeals to investors seeking high liquidity and trust in a well-established product. Trading volume of the ETF is hefty, making it especially attractive for frequent traders. However, its higher expense ratio and market price may deter cost-conscious retail investors.
The iShares Gold Trust ETF, on the other hand, is priced at around $50 per share with a lower 0.25% expense ratio. It offers a more economical entry point for gold investors. Although no match for GLD&#8217;s trading volume, IAU is still highly liquid and considered a viable choice for retail investors.
See Also: <a href="https://www.benzinga.com/news/large-cap/25/01/43137560/golds-blowout-rally-puts-spotlight-on-miners-will-they-finally-catch-up">Gold&#8217;s Blowout Rally Puts Spotlight On Miners: Will They Finally Catch Up?</a> 
Why It Matters: The rally is fueled by a weaker dollar and growing uncertainty surrounding Trump's proposed policies, including sweeping tariffs. Some investors fear his decisions will trigger trade wars and heighten market volatility.
Gold, as ever, remains a safe bet for risk-averse investors. While physical bullion remains a traditional choice, its limitations— such as storage costs, premiums, and liquidity challenges — make gold ETFs a more practical alternative for modern investors.
Although gold prices pulled back slightly today, it is possible that this is due to traders booking profits after the sharp ascent, and the movement is still bullish for the metal.
A walk down the memory lane shows us that gold has historically thrived during Trump&#8217;s presidency. When he assumed office in 2017, gold prices were near $1,200 per ounce, soaring to $1,957 per ounce by January 2021, as pointed out in a report in FXEmpire.
Now, in Trump's second term, the &#8220;Tariff Man&#8221; — a self-proclamation he made during his first term — is <a href="https://www.benzinga.com/government/regulations/25/01/43162941/trumps-second-term-sparks-market-jitters-with-trade-regulation-expansion-plans">introducing aggressive policies</a>, further stoking uncertainty. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#8230;.I am a Tariff Man. When people or countries come in to raid the great wealth of our Nation, I want them to pay for the privilege of doing so. It will always be the best way to max out our economic power. We are right now taking in $billions in Tariffs. MAKE AMERICA RICH AGAIN
&mdash; Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/1069970500535902208?ref_src=twsrc%5Etfw">December 4, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His proposals to impose 25% tariffs on Mexico and Canada by Feb. 1 and to levy a <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">10% tariff on Chinese imports</a> could impact global trade dynamics.
Just an example of why the markets are volatile, Canada is one of the world's largest producers of gold and a GSC Commodity Intelligence study revealed that the U.S. is the world&#8217;s largest importer of Canadian gold. A 25% tariff on imports from Canada might impact overall U.S. imports. See Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43159032/defiance-quantum-etf-hits-1-billion-milestone-as-ceo-talks-future-of-industry">Defiance Quantum ETF Hits $1 Billion Milestone As CEO Talks Future Of Industry</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

SPDR Gold Shares Vs. iShares Gold Trust: Two Shiny ETFs In Focus As 'Tariff Man' Trump Fuels Uncertainty

Raymond James analyst John Freeman maintains Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>) with a Strong Buy and raises the price target from $19 to $23.

Price Target

Raymond James Maintains Strong Buy on Kimbell Royalty Partners, Raises Price Target to $23

MCTR

CTRL Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 113.6%

Raymond James analyst John Freeman maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Strong Buy and raises the price target from $167 to $175.

Raymond James Maintains Strong Buy on EOG Resources, Raises Price Target to $175

DWTX

Dogwood Therapeutics Shares Resume Trading

The defense and space sector is experiencing a shift, with Voyager Technologies filing for an IPO as the industry gains momentum under the Trump administration. The Denver-based firm, which is developing a commercial space station with NASA funding, also has a growing <a href="https://www.benzinga.com/topic/defense">defense and national security</a> division, with direct ties to Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
Voyager, expected to be valued between $2 billion and $3 billion, has a strategic partnership with Palantir, integrating its AI capabilities into defense projects, The Wall Street Journal <a href="https://www.wsj.com/finance/defense-and-space-company-voyager-technologies-files-to-go-public-d020a807">reports</a>. Palantir is also an investor in Voyager, further cementing its footprint in national security.
As the industry sees a potential resurgence, Palantir's AI-driven solutions could gain even more traction in both government and commercial applications.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/01/43156862/tesla-rivals-rivian-lucid-fall-sharply-after-donald-trump-revokes-bidens-ev-targets-freezes-infra-funding-heres-what-technical-analysis-says">Tesla Rivals Rivian, Lucid Fall Sharply After Donald Trump Revokes Biden&#8217;s EV Targets, Freezes Infra Funding: Here&#8217;s What Technical Analysis Says</a>
<h2 class="wp-block-heading">PLTR Stock Chart: Bullish But Watch The Levels</h2>
PLTR stock has had an explosive year, gaining 343.57% over the past 12 months and 166.82% in the last six months.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="638" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082001/Screenshot-2025-01-23-at-6.47.33-PM.png" alt="" class="wp-image-746786" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082001/Screenshot-2025-01-23-at-6.47.33-PM.png 638w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082001/Screenshot-2025-01-23-at-6.47.33-PM-300x232.png 300w" sizes="(max-width: 638px) 100vw, 638px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012325&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
While year-to-date gains of 2.23% suggest a more measured climb, technical indicators remain largely bullish. The stock is trading above its eight-day, 20-day and 50-day simple moving averages (SMAs), signaling continued strength. However, its 20-day SMA sits right below PLTR stock price, which could offer a short-term resistance level if the price dips below it. 
The MACD (moving average convergence/divergence) indicator, at 0.59, boosts the bullish momentum, and RSI (relative strength index) at 56.74 keeps PLTR stock in neutral territory.
<h2 class="wp-block-heading">PLTR Gains Favor As AI, Defense Bets Grow</h2>
If the battlefield action wasn't enough, Palantir's stock is also charging ahead. Wedbush analyst Dan Ives, a long-time PLTR bull, just raised <a href="https://www.benzinga.com/general/market-summary/25/01/43157322/pltr-stock-is-up-166-in-last-6-months-now-dan-ives-sees-room-for-17-more-growth-our-recent-checks-and-growing-confidenceis-key-to-the-bull-thesis">his price target to $90</a>, a 19% upside from current levels.
The optimism isn't just about defense contracts—Palantir's commercial AI business is growing at a pace that Wall Street might be underestimating. Wedbush sees the company's U.S. commercial revenue surging past $1 billion, reinforcing its position as a top AI play.
Additionally, Palantir stands to benefit from Project Stargate, a colossal $500 billion U.S. AI infrastructure initiative. As AI spending accelerates, the company's role in national security and enterprise applications could turn it into an even bigger powerhouse.
With booming commercial AI prospects, deepening defense ties, and bullish analyst sentiment, Palantir's stock story is far from over. If momentum holds, $90 might not be far off.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126103/oracles-ai-moonshot-why-project-stargate-could-propel-orcl-stock-higher">Oracle&#8217;s AI Moonshot: Why Project Stargate Could Propel ORCL Stock Higher</a></li>
</ul>
Photo: Shutterstock

Technicals

IPOs

Tech

PLTR

Palantir's AI, Defense Bets Gain Traction As Voyager Technologies Eyes IPO

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and raises the price target from $60 to $65.

Needham Maintains Buy on WNS (Hldgs), Raises Price Target to $65

Dogwood Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 732.1%

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

Reiteration

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

Live On CNBC, Josh Brown Discusses Home Depot On Segment Titled "Josh's Best Stocks"

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Buy and maintains $16 price target.

ATXS

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target

Small Cap

Press Releases

HUMBLE & FUME INC. ANNOUNCES APPROVAL AND VESTING ORDERS

Comments

Humble & Fume Inc

Humble & Fume Inc (HUMBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga